Homepage > Core Laboratory
> Anti-Glutamic Acid Decarboxylase (GAD) Antibodies
Core Laboratory
11. Anti-Glutamic Acid Decarboxylase (GAD) Antibodies
The patient samples are incubated for two hours with human recombinant I125 GAD65. During this incubation, antibody binds to tracer. Protein A is added and the tubes are incubated for one hour during which time the antibodies present are bound by Protein A. Assay buffer is then added and the tubes are centrifuged. After centrifugation, the supernatants are decanted or aspirated. The amount of radioactivity in the pellets is directly proportional to the amount of antibody contained in the samples.
References:
- Tuomilehto, Jaakko et al., "Antibodies to Glutamic Acid Decarboxylase as Predictors of Insulin-Dependent Diabetes Before Clinical Onset of Disease", The Lancet 343: 1383-85, 1994.
- Verge, Charles F. et al., "Prediction of Type I Diabetes in First-Degree Relatives Using a Combination of Insulin, GAD and ICA512bdc/IA-2 Autoantibodies", Diabetes 45: 926-933, 1996.
Interassay coefficient of variation (CV):
Sample 1 = 3.6% (n=11, mean=4.2, sd=0.15)
Sample 2 = 5.1% (n=11, mean=25.0, sd=1.28)
Detection Limit:
1 U/mL
For more information, please contact the Core Laboratory manager or director.